Mechanism and Research Interest

Primary Biological Pathway: Enhanced Bioavailability via IGFBP Evasion The primary research interest in IGF-1 LR3 stems from its pharmacokinetics. In physiological conditions, IGFBPs act as carrier proteins that inhibit IGF-1 receptor interaction. IGF-1 LR3 evades this inhibition, maintaining high plasma concentrations of the unbound peptide. Research utilising the 1mg pen focuses on quantifying the Type 1 IGF Receptor (IGF-1R) activation in tissues that are typically shielded by high local concentrations of IGFBPs, such as the kidney and the gut, providing a model for “unrestricted” anabolic signalling.

Secondary Research Finding: Promotion of Hyperplasia IGF-1 LR3 is distinct from other anabolic agents in its ability to stimulate hyperplasia (cell division) in addition to hypertrophy (cell enlargement). It activates the MAPK/ERK pathway to trigger the proliferation of satellite cells—the stem cells of skeletal muscle. The 1mg format provides the necessary molar load to sustain this proliferative signal over weeks, allowing researchers to measure the net increase in myofiber number and the fusion of new myonuclei in models of muscle wasting or denervation atrophy.

Tertiary Research Finding: Nutrient Partitioning and Insulin Sensitivity IGF-1 LR3 acts as a potent nutrient partitioning agent. It stimulates glucose uptake in muscle tissue via the translocation of GLUT4 transporters, similar to insulin but without the risk of lipogenesis (fat storage). Conversely, it promotes lipolysis in adipose tissue. Researchers use the 1mg pen in models of Metabolic Syndrome to investigate whether chronic IGF-1 LR3 administration can reverse insulin resistance and improve body composition by shifting substrate utilisation from fat storage to muscle oxidation.

Long-term Genomic and Safety Observations Given its potency as a survival factor, long-term safety studies focus on the risk of unchecked cell proliferation. Genomic toxicology assays utilising the 1mg dose monitor the expression of Bcl-2 (anti-apoptotic) and Bax (pro-apoptotic) genes to ensure that the peptide does not induce a tumorigenic phenotype in tissues with high turnover rates, such as the intestinal epithelium.

Product Specifications

• Purity: Validated at >98+% via High-Performance Liquid Chromatography (HPLC) and SDS-PAGE. We strictly verify the recombinant synthesis process to ensure the peptide is free from bacterial endotoxins (LPS), which is critical for systemic administration.

• Appearance: The 3ml pen contains a clear, colourless, sterile liquid.

• Precision: The pen delivery system features a micro-click mechanism. This allows for the administration of precise, higher-volume doses required for systemic saturation studies, distinguishing it from the 0.1mg micro-dosing pen.

• Storage: The product must be stored at 2∘C to 8∘C.

Storage and Shipping Guidelines

Refrigeration and Shelf Life The IGF-1 LR3 1mg Pen is a temperature-sensitive recombinant protein. It must be refrigerated (2∘C to 8∘C). The shelf life is 12 months in the sealed state. Once the pen is accessed, the bacteriostatic environment preserves the solution for 28 days. Researchers should note that the 1mg concentration is more stable against surface adsorption than the 0.1mg variant, but strict cold-chain maintenance is still required to prevent protein unfolding.

Shipping Stability We utilise medical-grade thermal packaging. The peptide is stable for up to 72 hours at ambient UK temperatures. However, to preserve the tertiary structure essential for receptor binding, we strongly recommend selecting the fastest available shipping option.

Freezing Warning Do not freeze. Freezing causes the formation of ice crystals that can denature the protein. A denatured growth factor may aggregate, leading to a loss of solubility and bioactivity. Using a frozen/thawed pen will likely result in inconsistent anabolic data.

Why Choose the Peptide Pro 3ml Pen Format?

The IGF-1 LR3 1mg Pen is the definitive tool for Systemic and Chronic Research. While the 0.1mg pen is designed for cell culture or micro-injections, the 1mg pen provides the capacity needed for longitudinal animal studies (e.g., rodent or lagomorph models).

It eliminates the variability of manual reconstitution, providing a verified high-concentration stock that ensures consistent systemic exposure levels. This is vital for studies measuring global metabolic shifts rather than local tissue effects.

For researchers conducting comparative anabolic studies, we recommend referencing:

• IGF-1 LR3 0.1mg:  (For high-sensitivity/localised applications).

• MGF (Mechano Growth Factor) 2mg: (For research into the splice variant specific to the initial phase of muscle repair).

Disclaimer

This product is strictly for Research Use Only (RUO). It is not intended for human consumption, injection (e.g., for bodybuilding or performance enhancement), therapeutic use, or diagnostic procedures. The information provided is for educational and scientific reference only. Purchase is restricted to verified research institutions and qualified individuals. Any evidence of intended misuse for human application will result in immediate order cancellation and blacklisting, in compliance with UK research chemical regulations.